Kabazitaksel Sandoz

Cabazitaxel, the active ingredient in Kabazitaksel Sandoz, is a Taxane presented as a solution for injection for intravenous use. It treats metastatic castration‑resistant prostate cancer after prior docetaxel therapy in patients with disease progression. The drug belongs to the taxane class of antineoplastic agents and works by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis of cancer cells.

GNH USA supplies Kabazitaksel Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide with consistent quality and regulatory compliance.

Cabazitaxel is a taxane chemotherapy used in the treatment pathway for advanced prostate cancer.

- Metastatic castration‑resistant prostate cancer after docetaxel: provides an additional line of therapy to improve overall survival. - Prostate cancer with progression despite androgen‑deprivation therapy: offers a chemotherapy option when hormonal treatment fails. - Advanced prostate cancer not responding to prior taxane chemotherapy: delivers an alternative mechanism of action for disease control.

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Anemia: lowered red blood cell levels causing weakness. - Nausea: upset stomach often accompanied by vomiting. - Diarrhea: loose stools that may lead to dehydration. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Cardiac toxicity: arrhythmias or decreased heart function. - Pulmonary embolism: blood clot in the lungs presenting with sudden breathlessness. - Life‑threatening infections: sepsis due to immunosuppression. - Death: rare but possible in cases of severe toxicity.

Before initiating Cabazitaxel therapy, clinicians should assess patient suitability and monitor for potential complications.

- Monitor blood counts: perform regular CBC to detect neutropenia and anemia. - Assess hepatic function: check liver enzymes as cabazitaxel is metabolized hepatically. - Evaluate for hypersensitivity: observe for infusion‑related reactions during administration. - Avoid use in patients with active severe infection: risk of worsening infection due to myelosuppression. - Use caution in elderly or frail patients: increased susceptibility to toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase cabazitaxel exposure and toxicity. - Concurrent myelosuppressive agents: heighten risk of severe neutropenia and anemia. - Live vaccines: immunosuppression can reduce vaccine effectiveness and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower cabazitaxel levels, reducing effectiveness. - Anticoagulants (e.g., warfarin, DOACs): increased bleeding risk due to platelet effects. - Diuretics: potential for electrolyte disturbances when combined with fluid shifts during infusion.